SEC Filing Summary: Access Pharmaceuticals, Inc. (10-K)
Business Context and Reporting Period
Company: Access Pharmaceuticals, Inc. (formerly ABEONA THERAPEUTICS INC. in metadata, but filing identifies Access Pharmaceuticals, Inc.)
Period: Fiscal year ended December 31, 2009
Industry: Emerging biopharmaceutical company focused on nanopolymer chemistry and drug delivery technologies.
Key Developments: The company closed the acquisition of MacroChem Corporation on February 25, 2009, recorded under the pooling-of-interest method due to common control. The portfolio includes one FDA-cleared product (MuGard™ for oral mucositis), two Phase 2 candidates (ProLindac™ for cancer, Thiarabine for cancer), and pre-clinical oral delivery technologies (Cobalamin™).
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenue | $352,000 | $291,000 |
| Net Loss | $(17,340,000) | $(31,431,000) |
| Net Loss (Common Stockholders) | $(19,226,000) | $(34,789,000) |
| Loss Per Share (Basic/Diluted) | $(1.63) | $(4.16) |
| Research & Development Expenses | $2,657,000 | $23,235,000 |
| General & Administrative Expenses | $7,112,000 | $7,463,000 |
| Cash and Cash Equivalents (Dec 31, 2009) | $607,000 | $2,677,000 |
| Working Capital Deficit | $(7,949,000) | $(4,613,000) |
| Accumulated Deficit | $(241,807,000) | $(235,985,000) |
Debt & Liquidity: The company has a $5.5 million unsecured convertible note due September 13, 2011. As of March 18, 2010, cash was approximately $4.5 million. The net cash burn rate for 2009 was approximately $172,000 per month, with a projected burn rate of $450,000 per month for the following twelve months.
Material Changes vs. Prior Period
- Revenue Increase: Total revenue increased by $61,000 (21%) driven by licensing revenue ($315,000 vs. $118,000) and the recognition of royalty revenue ($37,000 vs. $0). Sponsored R&D revenue dropped to zero as the 2008 agreement concluded.
- Expense Reduction: Total operating expenses decreased by $20.99 million. R&D expenses dropped significantly ($20.58 million decrease) primarily due to the absence of one-time non-cash in-process R&D charges from the Somanta and Virium acquisitions that occurred in 2008.
- Derivative Liability: A new line item, "Loss on change in fair value of derivative," appeared in 2009 totaling $7.15 million. This resulted from the adoption of FASB ASC 815 (EITF 07-5), requiring the reclassification of certain warrants and preferred stock features from equity to liability status.
- Acquisition Impact: The 2009 financials include the combined results of Access and MacroChem (acquired Feb 2009) on a retroactive basis due to common control.
Guidance, Outlook, and Risks
Outlook: Management projects capital resources will fund operations into the first quarter of 2011. The company expects to launch MuGard in North America in Q2 2010. ProLindac is advancing into combination trials for ovarian cancer. The company anticipates continued losses as it invests in clinical trials and regulatory compliance.
Risks & Contingencies:
- Going Concern: The independent auditor included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern due to recurring losses and liquidity position.
- Capital Needs: The company requires substantial additional capital to fund operations and development. Failure to raise funds could force the delay or elimination of R&D programs.
- Debt Maturity: The $5.5 million convertible note matures in 2011; the company may be unable to repay it at maturity.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to a lack of segregation of duties (all financial reporting performed by the CFO) and insufficient accounting staff.
- Regulatory: Success depends on FDA approvals for drug candidates, which are uncertain and costly.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projected $450,000 monthly burn rate and the sufficiency of current cash ($4.5M as of March 2010) to reach Q1 2011.
- Debt Repayment: Assess the feasibility of repaying the $5.5 million convertible note due in September 2011, including potential refinancing or conversion terms.
- Derivative Accounting: Review the impact of the $7.15 million derivative loss on future earnings and the valuation assumptions used for the warrant liabilities.
- Commercialization Timeline: Confirm the Q2 2010 launch date for MuGard in North America and the status of reimbursement strategies.
- Internal Controls: Monitor progress in hiring accounting staff and implementing segregation of duties to remediate the material weakness in financial reporting.